Diurnal Response Window - Time-of-Day Drug Response as Pharmacodiagnostic Probe

1 Lévi et al. 2024 — Circadian Regulation of Drug Responses

Full Citation:: Lévi FA, Okyar A, Hadadi E, Innominato PF, Ballesta A. Circadian regulation of drug responses: toward sex-specific and personalized chronotherapy. Annual Review of Pharmacology and Toxicology. 2024;64:89–114. (Lévi et al. 2024) DOI:: 10.1146/annurev-pharmtox-051920-095416 PMID:: 37722720 Published:: January 23, 2024 Study Design:: Comprehensive review Key Findings::

- Comprehensive framework integrating molecular clocks into personalized chronotherapy
- Sexually dimorphic circadian drug responses identified across multiple drug classes (chemotherapy, immunotherapy, cardiovascular, metabolic, inflammatory, neurological)
- Proper administration timing confirmed to improve tolerability/efficacy
- Introduces chronofit vs nonchronofit patient classification based on circadian function robustness
- Chronobiotics (drugs targeting the circadian clock) as emerging pharmacological class
- Recommends integration of remote longitudinal circadian monitoring, single-timepoint biopsy-based clock function prediction, and multiscale biorhythmic mathematical modelling

Relevance:: Foundational framework for the diurnal response window concept. Introduces key conceptual vocabulary: chronopharmacology, chronotherapy, molecular clock function prediction. Directly relevant to classifying ME/CFS patients by circadian robustness for probe interpretation — chronofit patients would show cleaner diurnal drug response differences. Certainty Assessment::

- *Quality:*: High (Annual Review of Pharmacology and Toxicology; top-tier review)
- *Sample:*: N/A (review)
- *Replication:*: Synthesizes multiple clinical domains
- *Score:*: 0.85 (weight: 0.75; discounted: 0.64)

2 Livieratos et al. 2025 — Post-Infectious Fatigue and Circadian Rhythm Disruption

Full Citation:: Livieratos A, Lockley SW, Tsiodras S. Post infectious fatigue and circadian rhythm disruption in long-COVID and other infections: a need for further research. EClinicalMedicine. 2025;80:103073. (Livieratos, Lockley, and Tsiodras 2025) DOI:: 10.1016/j.eclinm.2025.103073 PMID:: 39896874 PMCID:: PMC11787434 Published:: January 18, 2025 Study Design:: Narrative review Key Findings::

- Post-infectious fatigue and sleep disturbances intimately linked to circadian rhythm disruption driven by SARS-CoV-2 infection
- Dysregulation of core clock genes: CLOCK, BMAL1, PER2
- Mitochondrial dysfunction impairing oxidative phosphorylation
- Cytokine-induced neuroinflammation (IL-6, TNF-α) as circadian disruptor
- Epigenetic changes including DNA methylation at clock-related loci, particularly in peripheral tissues
- Systemic circadian dysregulation identified as molecular hallmark of post-infectious fatigue syndromes

Relevance:: Most directly relevant paper to ME/CFS circadian disruption. Provides molecular basis (clock genes, mitochondrial dysfunction, epigenetic modifications) for why diurnal drug response windows would be abnormal in ME/CFS — the disrupted circadian clock creates an exaggerated diurnal signal-to-noise ratio for drug response differences. Argues that circadian disruption is not merely a symptom but a core pathophysiological mechanism. Certainty Assessment::

- *Quality:*: Medium-High (EClinicalMedicine/Lancet group; comprehensive mechanistic synthesis)
- *Sample:*: N/A (review; Long COVID focus rather than classic ME/CFS)
- *Replication:*: Mechanistic pathways still largely preclinical
- *Score:*: 0.65 (weight: 0.85; discounted: 0.55)

3 Woo et al. 2026 — Neuroendocrine Signature of ME/CFS (Meta-Analysis)

Full Citation:: Woo TW, Choi YJ, Kim JY, Lee JS, Son CG. Neuroendocrine signature of ME/CFS: Meta-analytic evidence for bioactive cortisol deficit and exaggerated feedback sensitivity. Molecular Psychiatry. 2026. Online ahead of print. (Woo et al. 2026) DOI:: 10.1038/s41380-026-03608-1 PMID:: 42026257 Published:: April 23, 2026 (online ahead of print) Study Design:: Systematic review and meta-analysis Sample Size:: 46 independent datasets; 1,388 ME/CFS patients (71.9% female; mean age 37.3 ± 6.2 yrs); 1,349 matched healthy controls Diagnostic Criteria:: varied (Fukuda, CCC, IOM across 46 included studies) Key Findings::

- Lower salivary cortisol at awakening and in the morning compared to controls
- Reduced 24-hour urinary cortisol and hair cortisol (cumulative output measures)
- Impaired cortisol release in response to ACTH stimulation (adrenal sensitivity reduced)
- Exaggerated cortisol suppression following glucocorticoid administration (enhanced negative feedback)
- Consistent pattern across measurement matrices: reduced free cortisol availability + enhanced HPA-axis negative feedback sensitivity

Relevance:: Highest-certainty paper in the diurnal response window evidence base. Quantifies the blunted diurnal cortisol rhythm in ME/CFS — the physiological substrate that the diurnal response window probe exploits. The exaggerated negative feedback sensitivity suggests drugs that modulate the HPA axis (corticosteroids, CRH antagonists, glucocorticoid receptor modulators) will show amplified diurnal response differences in ME/CFS compared to healthy controls. Provides effect-size benchmarks for power calculations in future chronopharmacology studies targeting ME/CFS. Certainty Assessment::

- *Quality:*: High (Molecular Psychiatry; systematic review with meta-analysis; 46 datasets)
- *Sample:*: Large (n=2,737 total included; largest HPA meta-analysis in ME/CFS)
- *Replication:*: Meta-analytic aggregation of 46 independent studies
- *Score:*: 0.88 (weight: 1.00; discounted: 0.88)

4 Okyar et al. 2024 — Circadian Timing System and Drug Metabolism

Full Citation:: Okyar A, Ozturk Civelek D, Akyel YK, Surme S, Pala Kara Z, Kavakli IH. The role of the circadian timing system on drug metabolism and detoxification: an update. Expert Opinion on Drug Metabolism & Toxicology. 2024;20(6):503–517. (Okyar et al. 2024) DOI:: 10.1080/17425255.2024.2356167 PMID:: 38753451 Published:: June 2024 Study Design:: Expert review Key Findings::

- ABC and SLC transporter families in intestine, liver, and kidney show dominant circadian regulation at the transcriptional level
- CYP450 systems in intestine, liver, and kidney under circadian clock control via CLOCK:BMAL1 binding to E-box elements in CYP gene promoters
- Circadian efflux control at blood-brain barrier documented — CNS drug penetration varies by time of day
- Sex-related circadian changes in metabolism and detoxification processes identified
- Better understanding of coupling between central clock and circadian metabolism/transport contributes to rational chronotherapy

Relevance:: PK arm of the diurnal response window probe. If a drug shows time-of-day efficacy differences, the Okyar framework allows differential attribution to PK (circadian metabolism/clearance) vs PD (circadian receptor expression at the target). The two must be disentangled for valid mechanistic inference. Identifies specific CYP isoforms and transporter families with known circadian expression for systematic probe design: a drug whose response varies by time of day and whose primary metabolism is through a non-circadian CYP isoform is likely showing PD-mediated diurnal variation. Certainty Assessment::

- *Quality:*: Medium-High (Expert Opinion on Drug Metabolism & Toxicology; authoritative but not systematic)
- *Sample:*: N/A (review; preclinical + clinical pharmacology literature)
- *Replication:*: Well-established chronopharmacology principle supported across multiple independent labs
- *Score:*: 0.78 (weight: 0.75; discounted: 0.59)

5 Hermida et al. 2021 — Trial Design Guidelines for Ingestion-Time Chronopharmacology

Full Citation:: Hermida RC, Smolensky MH, Balan H, et al. Guidelines for the design and conduct of human clinical trials on ingestion-time differences — chronopharmacology and chronotherapy — of hypertension medications. Chronobiology International. 2021;38(1):1–26. (Hermida et al. 2021) DOI:: 10.1080/07420528.2020.1850468 PMID:: 33342316 PMCID:: PMC8112296 Published:: January 2021 Study Design:: Position statement / methodological guidelines Key Findings::

- Defines 8-point minimum guidelines for chronopharmacology trials: recruitment restricted to ABPM-diagnosed hypertensives with comparable activity/sleep routines; treatment times selected by internal biological time (sleep/wake cycle) not clock time; ABPM as primary or sole BP assessment method; asleep BP mean and sleep-time relative decline calculated per individual; adjusted calculation procedure for ABPM means (not arithmetic averages); validated devices hourly over ≥48h; minimum sample size calculation by proper statistical methods; randomized double-blind or crossover design with adequate washout
- Reviews >150 human hypertension chronopharmacology trials (1974–present) documenting diverse protocols of suboptimal or defective design
- Common flaws: time-of-day vs circadian-time confusion, underpowered samples, inadequate washout, wake-time office BP rather than ABPM
- Prior studies mostly small sample size and statistically underpowered

Relevance:: Provides methodological template for designing diurnal response window studies in ME/CFS. Critical design elements directly applicable: alignment to individual sleep/wake cycle (not clock time), multi-day monitoring (≥48h), differentiation of circadian-phase-based vs clock-time-based timing, adequate power calculations, and blinding. These design elements prevent the common confound where “morning vs evening” studies conflate circadian phase with time since awakening. Certainty Assessment::

- *Quality:*: High (Chronobiology International; multi-center consensus; 22 co-authors from international institutions)
- *Sample:*: N/A (methodological review; >150 trials)
- *Replication:*: Consensus position statement backed by comprehensive literature review
- *Score:*: 0.82 (weight: 0.75; discounted: 0.62)

6 Alten et al. 2015 — Delayed-Release Prednisone in RA (CAPRA-2 RCT)

Full Citation:: Alten R, Grahn A, Holt RJ, Rice P, Buttgereit F. Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis. RMD Open. 2015;1(1):e000134. (Alten et al. 2015) DOI:: 10.1136/rmdopen-2015-000134 PMID:: 26535146 PMCID:: PMC4623361 Published:: August 13, 2015 Study Design:: Double-blind randomized controlled trial Sample Size:: n=350 symptomatic RA patients on DMARDs; randomized 2:1 to DR-prednisone 5mg vs placebo (12 weeks) Diagnostic Criteria:: ACR/EULAR RA criteria Key Findings::

- Delayed-release prednisone (administered ~22:00, releases at ~02:00) significantly improved fatigue beyond DMARD alone (FACIT-F: +3.8 vs +1.6 placebo; p=0.0032)
- Improvement in FACIT-F correlated positively with clinical response
- Significantly greater improvement in SF-36 vitality score (+5.6, p=0.001), physical component (+2.3, p=0.0003), and FACT-G general quality of life (+2.6, p=0.0233)
- Mechanism: evening administration timed so drug release at ~02:00 coincides with nocturnal rise of pro-inflammatory cytokines (IL-6, TNF-α) that drive morning stiffness and fatigue

Relevance:: Proof-of-concept demonstration that timing of drug administration predicts efficacy specifically for the fatigue dimension — the exact probe logic. Establishes that chronotherapy for fatigue is clinically feasible, measurable, and significant. If evening prednisone improves RA fatigue by timing anti-inflammatory action to the nocturnal cytokine surge, the same principle is applicable to ME/CFS where nocturnal immune activation is suspected. Demonstrates that chronotherapy is not merely theoretical — it produces clinically meaningful effect sizes (FACIT-F 2.2 points above placebo). Certainty Assessment::

- *Quality:*: High (RMD Open; double-blind RCT; n=350)
- *Sample:*: RA population (not ME/CFS); commercial trial (Horizon Pharma)
- *Replication:*: Single RCT; CAPRA-1 (proof-of-concept) replicated by CAPRA-2
- *Score:*: 0.82 (weight: 0.75; discounted: 0.62)

7 Galbo & Kall 2016 — Circadian Variations in PMR

Full Citation:: Galbo H, Kall L. Circadian variations in clinical symptoms and concentrations of inflammatory cytokines, melatonin, and cortisol in polymyalgia rheumatica before and during prednisolone treatment: a controlled, observational, clinical experimental study. Arthritis Research & Therapy. 2016;18:174. (Galbo and Kall 2016) DOI:: 10.1186/s13075-016-1072-4 PMID:: 27455959 PMCID:: PMC4960703 Published:: July 26, 2016 Study Design:: Controlled observational study with repeated 24h measurements Sample Size:: n=10 glucocorticoid-naive PMR patients; n=7 non-PMR control subjects Diagnostic Criteria:: PMR clinical diagnosis Key Findings::

- Pain and stiffness peaked in early morning (plateau 04:00–08:00), declined to nadir at 16:00 (2P < 0.05)
- Plasma IL-6, IL-8, TNF-α, IL-1β, and IL-4 varied with diurnal time in both groups, peaking between 04:00 and 08:00
- Cytokine concentrations (except IL-1β) and IL-10 were higher in patients throughout 24h
- Melatonin and cortisol consistently higher in patients, peaking ~02:00 and ~08:00 respectively
- Prednisolone 20mg/day for 14 days abolished symptoms, normalized CRP, reduced melatonin, IL-6, IL-8, and TNF-α; IL-10 increased at 10:00–14:00
- Findings support melatonin → cytokine production → symptoms pathway, with cortisol acting as anti-inflammatory counter-regulator

Relevance:: Demonstrates diurnal symptom-cytokine coupling in an autoimmune fatigue condition — provides precedent for time-of-day drug testing in fatigue syndromes. The 04:00–08:00 inflammatory peak is the target window for chronotherapy. Extending this logic to ME/CFS: a drug effective at 08:00 but not 20:00 may reflect anti-cytokine action timed to the nocturnal inflammatory surge. A drug effective at 20:00 but not 08:00 may reflect an anticipatory anti-inflammatory mechanism. The cytokine time-course data provides the circadian biomarker against which drug response timing can be interpreted. Certainty Assessment::

- *Quality:*: Medium-High (Arthritis Research & Therapy; controlled, repeated-measures, biomarker-linked)
- *Sample:*: Very small (n=10 PMR); PMR ≠ ME/CFS; open-label prednisolone
- *Replication:*: Single-center (Copenhagen); single study
- *Score:*: 0.75 (weight: 0.65; discounted: 0.49)

8 Cutolo 2019 — Circadian Rhythms and Rheumatoid Arthritis

Full Citation:: Cutolo M. Circadian rhythms and rheumatoid arthritis. Joint Bone Spine. 2019;86(3):327–333. (Cutolo 2019) DOI:: 10.1016/j.jbspin.2018.09.003 PMID:: 30227223 Published:: May 2019 Study Design:: Review with clinical practice integration Key Findings::

- RA symptoms (joint pain, stiffness, functional disability) show circadian variation with early morning maximum
- Nighttime rise of pro-inflammatory cytokines (especially IL-6, TNF-α) precedes clinical symptoms
- Cortisol circadian rhythm relatively preserved but insufficient in magnitude to suppress the increased inflammation — relative adrenal insufficiency
- Melatonin stimulates production of inflammatory cytokines (contrasts with its sleep-promoting role)
- Chronotherapy with modified-release prednisone administered at bedtime delays drug release to ~02:00–04:00, optimizing cytokine suppression
- Circadian-informed timing of NSAIDs and DMARDs also under investigation

Relevance:: Clinical template for the diurnal probe concept. RA serves as the best-studied exemplar where timing of drug administration is mechanistically linked to diurnal pathophysiology (nocturnal cytokine surge → morning symptoms → bedtime drug timing). The “relative adrenal insufficiency” in RA is structurally analogous to the blunted cortisol axis in ME/CFS (Woo 2026) — if endogenous cortisol is already low, the diurnal drug response window for HPA-axis-modulating drugs may be amplified compared to healthy controls. Certainty Assessment::

- *Quality:*: High (Joint Bone Spine; authoritative review by senior rheumatology chronopharmacology researcher)
- *Sample:*: N/A (review; RA-specific)
- *Replication:*: Well-replicated clinical principle across RA literature
- *Score:*: 0.75 (weight: 0.70; discounted: 0.53)

9 Zaki et al. 2019 — Chronotherapeutics Review

Full Citation:: Zaki NFW, Yousif M, BaHammam AS, Spence DW, Bharti VK, Subramanian P, Pandi-Perumal SR. Chronotherapeutics: recognizing the importance of timing factors in the treatment of disease and sleep disorders. Clinical Neuropharmacology. 2019;42(3):80–87. (Zaki et al. 2019) DOI:: 10.1097/WNF.0000000000000341 PMID:: 31082833 Published:: May/June 2019 Study Design:: Narrative review Key Findings::

- Systematic description of chronopharmacology principles: the way biological processes are expressed throughout the 24-hour day affects drug response
- Defines key terms: chronopharmacology (timing effects on kinetics/dynamics), chronotherapeutics (timing to optimize efficacy/safety), chronotype (individual circadian preference)
- Reviews time-specified drug treatment for sleep disorders including hypnotics, melatonin/ramelteon, and wake-promoting agents
- Covers cardiovascular chronotherapy (evening ACE inhibitors, bedtime statins), respiratory disease (evening theophylline), cancer chronotherapy
- Chronotype as individual-difference factor — morning vs evening types may show opposite drug response timing
- Promotes adoption by researchers and clinicians

Relevance:: Accessible entry-point review covering drug classes commonly used in ME/CFS symptom management (antidepressants, hypnotics, stimulants) from a circadian perspective. Chronotype dimension is directly relevant: ME/CFS patients with phase-delayed chronotype (evening preference) may show different optimal drug timing than phase-advanced patients. The review explicitly positions chronopharmacology as an underutilized dimension of precision medicine. Certainty Assessment::

- *Quality:*: Low-Medium (Clinical Neuropharmacology; narrative review without systematic methodology)
- *Sample:*: N/A (review); selective coverage of drug classes
- *Replication:*: N/A (introductory review)
- *Score:*: 0.60 (weight: 0.75; discounted: 0.45)

10 Ohdo 2021 — Chrono-Drug Discovery Based on Circadian Rhythm

Full Citation:: Ohdo S. Chrono-drug discovery and development based on circadian rhythm of molecular, cellular and organ level. Biological & Pharmaceutical Bulletin. 2021;44(6):747–761. (Ohdo 2021) DOI:: 10.1248/bpb.b21-00277 PMID:: 34078807 Published:: 2021 Study Design:: Review Key Findings::

- Suprachiasmatic nucleus (SCN) as circadian pacemaker; clock genes (CLOCK/BMAL1/PER/CRY) regulate vast array of circadian rhythms in drug targets, transporters, and metabolizing enzymes
- Clock gene disruption linked to sleep disorders, metabolic syndromes, and cancer
- Chrono-DDS (drug delivery systems matching circadian rhythm) as emerging paradigm
- Circadian dynamics of cancer stem cells controlled by tumor microenvironment — timing-sensitive therapeutic windows
- Novel clock gene modulators (chronobiotics) being developed as therapeutic targets: case study of CKD model where clock-targeting inhibitor repressed renal inflammation
- Gene/antibody delivery targeting specific clock-controlled molecules

Relevance:: Molecular-level foundation for the diurnal response window probe. If a drug’s target (receptor, enzyme, transporter) is under circadian clock transcriptional control, the drug’s efficacy at different times of day reveals the functional integrity of the clock-gene pathway regulating that target. In ME/CFS patients where Livieratos 2025 documents clock gene dysregulation, the diurnal drug response window should be exaggerated — the disrupted clock amplifies the normally subtle diurnal variation in target expression. Identifies specific clock genes as potential pharmacodiagnostic targets. Certainty Assessment::

- *Quality:*: Medium (Biol Pharm Bull; review, primarily preclinical/cellular evidence)
- *Sample:*: N/A (review; cancer-centric examples)
- *Replication:*: Core clock mechanisms well-established across organisms; Chrono-DDS applications less replicated
- *Score:*: 0.65 (weight: 0.50; discounted: 0.33)

11 Guarnotta et al. 2021 — Adrenal Insufficiency Steroid Chronopharmacology

Full Citation:: Guarnotta V, Amodei R, Giordano C. Metabolic comorbidities of adrenal insufficiency: focus on steroid replacement therapy and chronopharmacology. Current Opinion in Pharmacology. 2021;60:123–132. (Guarnotta, Amodei, and Giordano 2021) DOI:: 10.1016/j.coph.2021.07.003 PMID:: 34416524 Published:: October 2021 Study Design:: Review Key Findings::

- In adrenal insufficiency, hydrocortisone replacement must mimic the physiological circadian cortisol rhythm: peak at ~08:00, trough at midnight
- Standard bid/tid dosing regimens fail to replicate the normal diurnal curve — supraphysiological peaks then subphysiological troughs
- Modified-release hydrocortisone formulations (dual-release, once-daily at bedtime; Chronocort) better approximate the physiological rhythm
- Circadian-matched replacement reduces metabolic comorbidities (obesity, insulin resistance, osteoporosis, cardiovascular risk) compared to flat-dosing regimens
- Quality of life improved when steroid replacement respects circadian control of HPA axis output
- Chronopharmacological approach is standard of care in modern adrenal insufficiency management

Relevance:: Directly relevant to ME/CFS where HPA axis output is blunted (Woo 2026). If ME/CFS patients have functional adrenal insufficiency (reduced cortisol availability + exaggerated feedback sensitivity), the diurnal timing of corticosteroid administration — or any drug that modulates HPA axis feedback — should produce amplified response differences compared to healthy controls. The adrenal insufficiency chronopharmacology experience demonstrates clinically: circadian-matched dosing is not merely a theoretical ideal, it produces measurable improvements in metabolic and quality-of-life outcomes. Certainty Assessment::

- *Quality:*: Medium-High (Current Opinion in Pharmacology; authoritative review)
- *Sample:*: N/A (review; adrenal insufficiency ≠ ME/CFS)
- *Replication:*: Supported by Chronocort and Plenadren clinical development programs
- *Score:*: 0.70 (weight: 0.60; discounted: 0.42)

12 Kuring et al. 2026 — Inflammatory Markers in Dementia (Meta-Analysis)

Full Citation:: Kuring JK, Mathias JL, Ward L, Tachas G. Inflammatory markers associated with dementia: a systematic review and meta-analysis. Journal of Psychiatric Research. 2026;197:26–40. (Kuring et al. 2026) DOI:: 10.1016/j.jpsychires.2026.02.044 PMID:: 41759353 Published:: February 2026 Study Design:: PRISMA/MOOSE-conforming systematic review and meta-analysis (41 studies; 3895 participants). CRD42020188244. Key Findings::

- AD is associated with inflammation independent of comorbid mental/physical conditions that cause inflammation. IL-17A (Hedges' g 0.74), IL-1α (0.57), IL-10 (0.59) elevated, each from 4 studies
- G-CSF (0.80), GM-CSF (0.44), IL-3 (1.39) elevated in AD (2 studies each); IL-3, G-CSF novel markers not examined by prior alzheimer meta-analyses
- Excluding comorbid inflammatory conditions removed the IL-6 and TNF-α elevations reported in older meta-analyses — comorbid conditions, not dementia itself, may have driven those signals
- VaD, DLB, FTD show tentative, divergent inflammatory profiles: IL-1α, IL-3, CCL18 higher in AD but lower in VaD/DLB/FTD
- Peripheral vs CSF discordance for IL-1β and TNF-α in AD (lower in CSF, no difference peripherally) — blood may not be a reliable proxy for CNS neuroinflammation
- Overlap evidence: IL-17A elevated in AD and in depression; G-CSF elevated in AD, depression, and PTSD — consistent with a mental-illness → inflammation → dementia pathway

Conclusion:: Supports the inflammatory-mediated neurodegeneration hypothesis: AD (and tentatively VaD/DLB/FTD) display inflammatory changes not attributable to comorbid inflammatory conditions. Whether inflammation is causal, prodromal, or epiphenomenal to dementia remains unresolved. Limitations:: Observational, cross-sectional included studies cannot establish causality; data for VaD/DLB/FTD and most markers limited (single studies); publication bias not assessable; dementia diagnoses clinical rather than biomarker-confirmed (possible mixed-dementia contamination); peripheral measures may not reflect CNS inflammation. Certainty Assessment::

- *Quality:*: High (peer-reviewed meta-analysis, PRISMA/MOOSE, 41 studies, large pooled n)
- *Sample:*: n=3895 (2256 dementia, 1639 controls)
- *Replication:*: Findings cross 41 included studies but individual markers mostly single-study
- *Score:*: 0.85 (weight: 0.75 [dementia ≈ other-disease general-population]; discounted: 0.64)

13 Kuring et al. 2023 — Inflammatory Markers in Depression/Anxiety/PTSD (Meta-Analysis)

Full Citation:: Kuring JK, Mathias JL, Ward L, Tachas G. Inflammatory markers in persons with clinically-significant depression, anxiety or PTSD: a systematic review and meta-analysis. Journal of Psychiatric Research. 2023;168:279–292. (Kuring et al. 2023) DOI:: 10.1016/j.jpsychires.2023.10.009 PMID:: 37931509 Published:: December 2023 Study Design:: PRISMA/MOOSE-conforming systematic review and meta-analysis of inflammatory markers in clinically-significant depression, anxiety, or PTSD. Key Findings::

- Evaluates the inflammatory-mediated neurodegeneration hypothesis from the mental-illness side: whether depression, anxiety, and PTSD are each associated with inflammation independent of comorbid inflammatory conditions
- Companion to the 2026 dementia meta-analysis; the 2026 paper compares dementia inflammatory profiles to these mental-illness profiles
- Provides the depression-side anchor for the hypothesis: IL-17A and G-CSF elevated in both AD (2026) and depression (2023) → shared inflammatory pathway candidate

Conclusion:: Establishes the mental-illness-associated inflammatory baseline against which dementia inflammation is compared, supporting the plausibility of a mental-illness → inflammation → dementia chain. Limitations:: Observational/cross-sectional included studies; cannot establish temporal or causal ordering between mental illness and inflammation. Certainty Assessment::

- *Quality:*: High (peer-reviewed meta-analysis, PRISMA/MOOSE)
- *Sample:*: Multi-study meta-analysis; large pooled n
- *Replication:*: Across multiple included studies per marker
- *Score:*: 0.80 (weight: 0.75 [mental-illness population, non-ME/CFS]; discounted: 0.60)

14 Strawbridge et al. 2019 — Inflammatory Proteins in CFS (Meta-Analysis)

Full Citation:: Strawbridge R, Sartor ML, Scott F, Cleare AJ. Inflammatory proteins are altered in chronic fatigue syndrome—A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews. 2019;107:69–83. (Strawbridge et al. 2019) DOI:: 10.1016/j.neubiorev.2019.08.011 PMID:: 31465778 Published:: December 2019 Study Design:: Systematic review and meta-analysis of circulating inflammatory protein levels in CFS vs healthy controls (42 studies). Key Findings::

- ME/CFS patients have significantly elevated TNF-α (ES 0.274, p\<0.001), IL-2 (0.203), IL-4 (0.373), TGF-β (0.967), and CRP (0.622)
- 12 other proteins measured did not differ between CFS and controls
- Provides the ME/CFS-side parallel: chronic fatigue is associated with a similar low-grade inflammatory profile to that seen in dementia — but the specific elevated markers differ (TNF-α/IL-4/TGF-β/CRP in CFS vs IL-17A/IL-1α/IL-10/G-CSF/IL-3 in AD)

Conclusion:: Supports an inflammatory component in CFS, though heterogeneity across studies indicates inflammation is not uniform across all patients — parallels the subgroup-specific inflammatory profiles argued in dementia. Limitations:: Substantial between-study heterogeneity; most studies not designed to test the inflammatory-mediated hypothesis; possible comorbidity confounding; case definitions varied. Certainty Assessment::

- *Quality:*: High (peer-reviewed meta-analysis, 42 studies)
- *Sample:*: 42 studies
- *Replication:*: Across multiple studies per protein
- *Score:*: 0.70 (weight: 1.00 [ME/CFS cohort]; discounted: 0.70)

15 Xiong et al. 2025 — AI-Driven Multi-Omics Modeling of ME/CFS (BioMapAI)

Full Citation:: Xiong R, Aiken E, Caldwell R, Vernon SD, Kozhaya L, Gunter C, Bateman L, Unutmaz D, Oh J. AI-driven multi-omics modeling of myalgic encephalomyelitis/chronic fatigue syndrome. Nature Medicine. 2025;31(9):2991–3001. (Xiong et al. 2025) DOI:: 10.1038/s41591-025-03788-3 PMID:: 40715814 Published:: 25 July 2025 (Epub); Sep 2025 (issue) Study Design:: Prospective longitudinal multi-omics cohort; supervised deep neural network (BioMapAI); explainable AI (SHAP). Key Findings::

- BioMapAI integrates gut metagenomics, plasma metabolomics, immune cell profiling, blood labs, and 12 clinical symptoms from 249 participants (96 healthy, 153 ME/CFS; 515 timepoints over 4 years)
- Disease classification AUC=0.99; validated on held-out and 4 independent external cohorts (Guo, Raijmakers microbiome; Germain, Che metabolome)
- Constructs a microbiome–immune–metabolome connectivity map adjusted for age/gender/clinical factors
- Dysbiotic crosstalk: decreased butyrate and branched-chain amino acid pathways; increased tryptophan and benzoate pathways, linked to GI symptoms
- Heightened inflammatory activity in mucosal-associated invariant T (MAIT) and γδ T cell subsets secreting IFN-γ and Granzyme A
- Increased benzoate→hippurate transformation associated with emotional disturbance, sleep issues, and fatigue
- Heterogeneity: fatigue persistently severe; emotional dysregulation variable; controls indistinguishable from patients on any single omics layer alone

Conclusion:: Provides systems-level integration of the gut microbiome, immune system, and plasma metabolome in ME/CFS, refining existing hypotheses (butyrate/BCAA deficiency, tryptophan diversion, immune activation, metabolic dysbiosis) and nominating a specific benzoate→hippurate–symptom axis. Limitations:: Symptom-specific biomarkers computed on the full dataset and not validated on held-out data; single-country (US) cohort, n=249; associative not causal; no interventional validation; competing interest (S.D. Vernon — The BioCollective kit vendor). Certainty Assessment::

- *Quality:*: High (top journal, rigorous multi-omics + AI)
- *Sample:*: n=249 ME/CFS cohort (96 healthy, 153 ME/CFS)
- *Replication:*: External validation in 4 independent cohorts; held-out validation partial (symptom-level gaps)
- *Score:*: 0.90 (weight: 1.00 [ME/CFS cohort]; discounted: 0.90)

16 Brigo et al. 2025 — Uremic Bacterial Metabolites in Post-COVID-19 Syndrome

Full Citation:: Brigo N, Mayr W, Taenzer M, Löffler-Ragg J, Schroll A, Engl S, Schütz B, Rappl P, Heine T, Weiss G, Kurz K. Concentrations of uremic bacterial metabolites in patients with post-COVID-19 syndrome. Frontiers in Cellular and Infection Microbiology. 2025;15:1582972. (Brigo et al. 2025) DOI:: 10.3389/fcimb.2025.1582972 PMID:: 40510799 Published:: 29 May 2025 Study Design:: Pilot case-control; mass-spectrometry urine metabolomics. Key Findings::

- Elevated tryptamine, HPHPA (4-hydroxyphenylpropionic acid), hippuric acid, and trimethylamine exclusively in patients with post-infectious syndromes (post-COVID and ME/CFS)
- Elevated bacterial uremic metabolites in 64% of post-COVID patients vs 37.5% of controls and ME/CFS
- Supports the gut-dysbiosis → microbial-metabolite → systemic-signaling axis overlapping post-infectious fatigue

Conclusion:: Urine metabolomic fingerprinting of bacterial metabolites is a promising approach for probing gut dysbiosis in post-infectious fatigue syndromes, consistent with the benzoate→hippurate axis highlighted by the Xiong model. Limitations:: Small pilot (n=41: 25 PCS, 8 ME/CFS, 8 controls); overall BUM levels not significantly different between groups; exploratory clustering. Certainty Assessment::

- *Quality:*: Adequate (peer-reviewed pilot)
- *Sample:*: Small (n=41)
- *Replication:*: Single study
- *Score:*: 0.30 (weight: 0.85 [post-infectious]; discounted: 0.26)

17 Malatji et al. 2017 — Fibromyalgia Diagnostic Metabolomics and Hippuric Acid

Full Citation:: Malatji BG, Meyer H, Mason S, Engelke UFH, Wevers RA, van Reenen M, Reinecke CJ. A diagnostic biomarker profile for fibromyalgia syndrome based on an NMR metabolomics study of selected patients and controls. BMC Neurology. 2017;17(1):88. (Malatji et al. 2017) DOI:: 10.1186/s12883-017-0863-9 PMID:: 28490352 Published:: 11 May 2017 Study Design:: Urinary 1H-NMR metabolomics; case-control with multiple control groups. Key Findings::

- Significant increases in gut-microbiome-related metabolites (hippuric, succinic, lactic acids) in fibromyalgia vs controls
- Diagnostic algorithm (succinic acid, taurine, creatine) achieved ROC AUC ~0.90
- Supports hippuric acid as a cross-condition marker of altered microbiome–host metabolite flux in chronic pain/fatigue

Conclusion:: Independent evidence that gut-microbiome-derived hippurate is elevated in a chronic pain syndrome overlapping ME/CFS, reinforcing the benzoate→hippurate axis the Xiong model links to symptoms. Limitations:: Small (n=18 FMS patients), single centre, largely female cohort; cross-sectional; associative. Certainty Assessment::

- *Quality:*: Adequate (peer-reviewed)
- *Sample:*: Small (n=18)
- *Replication:*: Single study
- *Score:*: 0.25 (weight: 0.80 [fibromyalgia]; discounted: 0.20)

18 Komaroff & Dantzer 2025 — Causes of Symptoms and Symptom Persistence in Long COVID and ME/CFS

Full Citation:: Komaroff AL, Dantzer R. Causes of symptoms and symptom persistence in long COVID and myalgic encephalomyelitis/chronic fatigue syndrome. Cell Reports Medicine. 2025;6(8):102259. (Komaroff and Dantzer 2025)
DOI:: 10.1016/j.xcrm.2025.102259
Key Findings::
- Long COVID and ME/CFS together affect an estimated 60–400 million people globally and share similar underlying biological abnormalities (autoantibodies against neural targets, endothelial dysfunction, acquired mitochondrial dysfunction, pro-inflammatory gut microbiome)
- Proposes that symptoms are additionally generated by ancient evolutionarily-conserved responses to vital threats — sickness behavior and torpor — mediated by recently discovered dedicated neural circuits (area postrema→brainstem; organum vasculosum→ventromedial preoptic area; median preoptic nucleus→torpor)
- These neural circuits constitute a symptom-generating pathway activated by neuroinflammation, which may be targetable therapeutically
- Symptom persistence is driven by persistent infectious agents (or their nucleic acids/antigens), residual tissue injury, defective resolution of inflammation, herpesvirus reactivation, gut dysbiosis, autoimmunity, a defective neural-circuit “switch,” and mutually reinforcing vicious cycles
- Treatment implication: target neuroinflammation directly; traditional anti-inflammatory drugs are unlikely to be effective, novel therapies required
Conclusion:: Provides an authoritative unifying synthesis in which the known peripheral abnormalities of long COVID and ME/CFS generate symptoms via neuroinflammation activating dedicated sickness-behavior and torpor neural circuits, with chronicity sustained by positive-feedback vicious cycles.
Limitations:: Review (not primary data); the dedicated sickness-behavior/torpor neural circuits have been identified in rodents and are only indirectly evidenced in humans; the neural-circuit model is speculative as applied to chronic illness.
Certainty Assessment::
- Quality:: High (peer-reviewed review, senior authors)
- Sample:: n/a (review)
- Replication:: n/a
- Score:: 0.78

19 Dantzer 2001 — Cytokine-Induced Sickness Behavior: Mechanisms and Implications

Full Citation:: Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann NY Acad Sci. 2001;933:222–234. (Dantzer 2001)
DOI:: 10.1111/j.1749-6632.2001.tb05827.x
Key Findings::
- Defines sickness behavior as a coordinated set of behavioral changes (lethargy, anorexia, anhedonia, social withdrawal) developing during infection
- Establishes the molecular mechanism: peripheral pro-inflammatory cytokines (IL-1, TNF-α) act on the brain via a fast afferent-nerve (vagal) pathway and a slow humoral pathway (choroid plexus, circumventricular organs)
- Frames sickness behavior as the expression of a central motivational state that reorganizes organism priorities to cope with infection
Conclusion:: The foundational paper establishing the neuroimmune (cytokine-driven) model of symptom generation that this review builds on.
Limitations:: Primarily acute-infection framework; plasticity mechanisms of the sickness motivational state not yet understood.
Certainty Assessment::
- Quality:: High (foundational, peer-reviewed)
- Sample:: n/a (review/framework)
- Replication:: n/a
- Score:: 0.70

20 Hrvatin et al. 2020 — Neurons that Regulate Mouse Torpor

Full Citation:: Hrvatin S, Sun S, Wilcox OF, Yao H, Lavin-Peter AJ, Cicconet M, et al. Neurons that regulate mouse torpor. Nature. 2020;583:115–121. (Hrvatin et al. 2020)
DOI:: 10.1038/s41586-020-2387-5
Key Findings::
- Identifies neurons in the median preoptic nucleus of the hypothalamus that regulate entry into and exit from torpor
- Optogenetic stimulation of these neurons triggers a full torpor-like hypometabolic state even without food deprivation or vital threat; can induce torpor in rats that do not naturally torpor
Conclusion:: Provides the neural-circuit basis for treating a torpor-like hypometabolic response — a metabolic analogue of sickness behavior — as a real, circuit-mediated phenomenon relevant to ME/CFS and long COVID hypometabolic changes.
Limitations:: Rodent study; the human relevance and the role of these circuits in chronic (not acute) hypometabolic states are not established.
Certainty Assessment::
- Quality:: High (Nature, optogenetics, replicated)
- Sample:: n/a (basic neuroscience)
- Replication:: Independent
- Score:: 0.62

21 Machado et al. 2025 — Preoptic EP3R Neurons Constitute a Two-Way Switch for Fever and Torpor

Full Citation:: Machado NLS, Lynch N, Costa LHA, Melville D, Kucukdereli H, Kaur S, et al. Preoptic EP3R neurons constitute a two-way switch for fever and torpor. Nature. 2025. (Machado et al. 2025)
DOI:: 10.1038/s41586-025-09056-1
Key Findings::
- Shows that preoptic EP3 receptor-expressing neurons act as a two-way switch mediating both fever and torpor
- Implies a single switchable neural node can route the organism between protective hypermetabolic (fever) and hypometabolic (torpor) states
Conclusion:: Directly supports the review’s hypothesis of a “defective neural circuit switch” — an on-off mechanism that could become stuck in the “on” (sickness/torpor) position, contributing to chronic symptom persistence.
Limitations:: Rodent study; whether a preoptic EP3R switch is chronically engaged in ME/CFS or long COVID is untested.
Certainty Assessment::
- Quality:: High (Nature)
- Sample:: n/a (basic neuroscience)
- Replication:: Recent single-report (2025)
- Score:: 0.62

22 Sommen et al. 2026 — Deep Immunophenotyping Reveals a Fatigue Signature in Long COVID

Full Citation:: Sommen SL, Segtnan S, Selvakumar J, Havdal LB, Stiansen-Sonerud T, Gjerstad J, et al. Long COVID: Deep single-cell immunophenotyping and machine learning reveal a general signature for fatigue. J Transl Med. 2026;24(1):736. (Sommen et al. 2026)
DOI:: 10.1186/s12967-026-08149-3
Key Findings::
- Deep single-cell immunophenotyping plus machine learning in long COVID identifies a general immunophenotypic signature associated with fatigue
- Demonstrates that persistent fatigue in long COVID is associated with an ongoing immune signature, not necessarily a serum inflammatory cytokine elevation
Conclusion:: Supports the model that persistent symptoms track immune-system state, consistent with a neuroinflammation-focused (rather than serum-cytokine) account of symptom persistence.
Limitations:: Single cohort; signature vs. causation not established; ME/CFS not directly studied.
Certainty Assessment::
- Quality:: Adequate (peer-reviewed, single study)
- Sample:: Medium cohort
- Replication:: Single study
- Score:: 0.50

23 Augustin et al. 2026 — Persistent Gut–Immune Axis Dysregulation in Long-Term Post-COVID Syndrome

Full Citation:: Augustin M, Picard L, Rauschning D, Zenev E, Pracht E, de Silva US, et al. Persistent Gut–Immune Axis dysregulation in long-term Post-COVID Syndrome: Insights from a prospective, observational, cross-sectional case-control study. Mucosal Immunology. 2026;19(3):100328. (Augustin et al. 2026)
DOI:: 10.1016/j.mucimm.2026.03.002
Key Findings::
- Prospective cross-sectional case-control study demonstrating persistent gut–immune axis dysregulation in long-term post-COVID syndrome
- Supports the persistence of gut dysbiosis and mucosal immune disturbance long after acute infection
Conclusion:: Provides empirical support for gut dysbiosis as one of the vicious-cycle drivers of symptom persistence in post-acute infection syndrome.
Limitations:: Cross-sectional (no longitudinal trajectory); long-COVID only, not ME/CFS.
Certainty Assessment::
- Quality:: Adequate (peer-reviewed, case-control)
- Sample:: Medium
- Replication:: Single study
- Score:: 0.50

24 Azcue et al. 2026 — GPCR Autoantibodies in Post-COVID Condition and Chronic Fatigue Syndrome

Full Citation:: Azcue N, Prada A, Del Pino R, Acera M, Fernández-Valle T, Ayo-Mentxakatorre N, et al. Involvement of autoantibodies against G protein-coupled receptors in post-COVID condition and Chronic Fatigue Syndrome. Scientific Reports. 2026;16:20609. (Azcue et al. 2026)
DOI:: 10.1038/s41598-026-49131-9
Key Findings::
- Case-control study examining functional GPCR autoantibodies in post-COVID condition and ME/CFS
- Relevant to the GPCR autoantibody hypothesis and to the shared autoantibody findings in long COVID and ME/CFS
Conclusion:: Independent recent evidence that GPCR autoantibodies — a candidate shared pathogenic abnormality — are present in both post-COVID condition and ME/CFS.
Limitations:: Case-control (association evidence); small-to-medium; severity stratification not emphasized.
Certainty Assessment::
- Quality:: Adequate (peer-reviewed, case-control)
- Sample:: Small-to-medium
- Replication:: Single study
- Score:: 0.45

25 Baraniuk et al. 2024 — Meta-Analysis of NK Cell Cytotoxicity in ME/CFS

Full Citation:: Baraniuk JN, Eaton-Fitch N, Marshall-Gradisnik S. Meta-analysis of natural killer cell cytotoxicity in myalgic encephalomyelitis/chronic fatigue syndrome. Frontiers in Immunology. 2024;15:1440643. (Baraniuk, Eaton-Fitch, and Marshall-Gradisnik 2024)
DOI:: 10.3389/fimmu.2024.1440643
Key Findings::
- Meta-analysis of 28 papers/55 E:T ratio datapoints; NK cell cytotoxicity in ME/CFS reduced to about half of healthy control levels (Hedges’ g 0.96, 95% CI 0.75–1.18)
- High heterogeneity explained by E:T ratios, methods, and potential outliers
Conclusion:: Confirms reproducible NK dysfunction in ME/CFS but the heterogeneity signals methodological sensitivity and warns against treating reduced NK cytotoxicity as a single invariant invariant defect — consistent with the review’s multi-abnormality, vicious-cycle view.
Limitations:: Meta-analysis heterogeneity; cannot establish whether reduced NK cytotoxicity is cause or consequence.
Certainty Assessment::
- Quality:: High (meta-analysis)
- Sample:: 28 studies
- Replication:: Reproducible finding, heterogeneous effect
- Score:: 0.62

26 Tuomaala et al. 2026 — TSPO-PET Glial Activation in Long COVID Limbic System

Full Citation:: Tuomaala J, Saraste M, Smith E, Kuusi M, Westerberg E, Honkonen E, et al. Association between post-COVID-19 neuropsychiatric symptoms and persistent glial activation in the limbic system: a TSPO PET study. J Neurol. 2026;273(5):298. (Tuomaala et al. 2026)
DOI:: 10.1007/s00415-026-13842-w
PMID:: 42059960
Study Design:: Case-control TSPO-PET ([11C]PK11195) imaging study with 3T MRI; 14 LC, 11 healthy controls, 13 MS controls
Key Findings::
- Global TSPO availability (DVR) was NOT elevated in LC compared to HCs — a partial null that constrains the magnitude and spatial extent of neuroinflammation in LC
- Limbic TSPO DVR correlated with LC severity: lower quality of life associated with higher DVRs in hippocampus, amygdala, and thalamus (rho = –0.83 to –0.70)
- Depression and anxiety correlated positively with DVRs in hippocampus and amygdala (rho = 0.75–0.97)
- White-matter TSPO DVR was lower in individuals with longer LC duration (over 16 months vs. under 16 months), suggesting neuroinflammation may partially subside over time
Conclusion:: Global neuroinflammation is not a uniform LC feature — but regional limbic glial activation is associated with symptom severity and neuropsychiatric burden, supporting a regionally-specific neuroinflammation→symptom model that aligns with the Komaroff-Dantzer 2025 neural-circuit hypothesis while constraining its spatial scope.
Limitations:: Small sample (n=14 LC); single TSPO radioligand ([11C]PK11195 has lower signal-to-noise than second-generation TSPO tracers); cross-sectional; cannot establish causation; long-COVID only, no ME/CFS arm.
Certainty Assessment::
- Quality:: Medium (first TSPO-PET study in LC; small n but gold-standard imaging methodology)
- Sample:: n=38 total (14 LC, 11 HC, 13 MS)
- Replication:: Single study; no TSPO-PET replication in LC yet
- Score:: 0.50

27 Mughal et al. 2025 — 3D Biofabricated Muscle Exposed to ME/CFS & LC Sera

Full Citation:: Mughal S, Andújar-Sánchez F, Sabater-Arcis M, Garrabou G, Fernández-Solà J, Alegre-Martin J, Sanmartin-Sentañes R, Castro-Marrero J, Esteve-Codina A, Casals E, Fernández-Costa JM, Ramón-Azcón J. Metabolic adaptation and fragility in healthy 3D in vitro skeletal muscle tissues exposed to chronic fatigue syndrome and Long COVID-19 sera. Biofabrication. 2025;17(4). (Mughal et al. 2025)
DOI:: 10.1088/1758-5090/adf66c
PMID:: 40744071
Study Design:: In vitro — healthy 3D biofabricated human skeletal muscle tissues exposed to ME/CFS and Long COVID patient sera for 48h, 96h, and 144h. Transcriptomics, mitochondrial imaging, contractile force measurement. Barcelona mega-collaboration (IBEC, IDIBAPS, Hospital Clinic, Vall d’Hebron, CNAG).
Key Findings::
- Short exposure (48h): significant reduction in contractile strength; upregulated protein translation, glycolytic enzymes, calcium dysregulation, myotube hypertrophy, mitochondrial hyperfusion
- Elevated mitochondrial oxygen consumption in ME/CFS-exposed tissues — paradoxically high respiration during initial adaptation
- Prolonged exposure (96–144h): muscle fragility and weakness, mitochondria fragment into toroidal conformation
- Proposed hypermetabolic adaptation model: muscle initially adapts via glycolysis → prolonged exposure causes mitochondrial and structural deterioration
- First 3D in vitro skeletal muscle model for ME/CFS/LC; first evidence of transient metabolic adaptation in engineered muscle
Conclusion:: Patient sera contain circulating factor(s) that induce a biphasic response in healthy muscle: initial adaptive glycolysis and hypermetabolism, followed by fragility and mitochondrial collapse. Suggests serum-borne mediators (cytokines, miRNA, exosomes, metabolites) drive muscle pathology independently of neural or vascular context.
Limitations:: In vitro model (population weight 0.40); small and heterogeneous patient sera sample; no neural or vascular components in model; short exposure times (max 6 days); unblinded exposure; single muscle tissue architecture; no direct patient muscle biopsy comparison within study.
Certainty Assessment::
- Quality:: Medium (novel methodology, rigorous multi-omics, but in vitro)
- Sample:: n=ME/CFS + LC sera (small, exact counts not in abstract)
- Replication:: Single study; no replication yet
- Score:: 0.26

28 Appelman et al. 2024 — Muscle Abnormalities Worsen After PEM in Long COVID

Full Citation:: Appelman B, Charlton BT, Goulding RP, Kerkhoff TJ, Breedveld EA, Noort W, Offringa C, Bloemers FW, van Weeghel M, Schomakers BV, Coelho P, Posthuma JJ, Aronica E, Joost Wiersinga W, van Vugt M, Wüst RCI. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nature Communications. 2024;15:17. (Appelman et al. 2024)
DOI:: 10.1038/s41467-023-44432-3
PMID:: 38177128
Study Design:: Longitudinal case-control (NCT05225688). n=25 Long COVID, n=21 healthy controls. Vastus lateralis biopsies before and after maximal exercise test. Metabolomics, histopathology, electron microscopy. Wüst lab, Vrije Universiteit Amsterdam.
Key Findings::
- Skeletal muscle structure associated with lower exercise capacity in Long COVID
- Local and systemic metabolic disturbances in patient muscle
- Severe exercise-induced myopathy after PEM induction — muscle damage not present at rest appears after exertion
- Tissue infiltration of amyloid-containing deposits in skeletal muscle — novel finding
- Glycolytic fiber type shift away from oxidative metabolism
Conclusion:: PEM involves acute structural damage to skeletal muscle with amyloid deposition and metabolic decompensation. Exercise intolerance is not simply deconditioning — it reflects active tissue pathology.
Limitations:: Long COVID only (no ME/CFS arm); single exercise bout; biopsy site may not represent whole-body muscle; cross-sectional temporal sampling.
Certainty Assessment::
- Quality:: High (Nature Communications, rigorous design)
- Sample:: n=46 (25 LC + 21 HC)
- Replication:: Consistent with prior muscle biopsy findings; Wüst lab replication series ongoing
- Score:: 0.68

29 Appelman et al. 2025 — Reply: Muscle Abnormalities in Long COVID

Full Citation:: Appelman B, Charlton BT, Goulding RP, Kerkhoff TJ, Breedveld EA, Noort W, Offringa C, Bloemers FW, van Weeghel M, Schomakers BV, Coelho P, Posthuma JJ, Aronica E, Wiersinga WJ, van Vugt M, Wüst RCI. Reply: Muscle abnormalities in long COVID. Nature Communications. 2025;16:1491. (Appelman et al. 2025)
DOI:: 10.1038/s41467-025-56431-7
Type:: Matters Arising reply (to Ranque et al. 2025, DOI 10.1038/s41467-025-56430-8). Same Wüst-lab Amsterdam cohort as (Appelman et al. 2024) and (Charlton et al. 2026).
Key Findings::
- Matched step-count analysis (5181 vs 4727 steps/day, patients vs controls) still shows −24% VO₂max (p=0.004) and −31% peak power (p=0.043) — physical activity level does not explain the exercise deficit
- Long COVID PEM patients show reduced gas exchange threshold and respiratory compensation point, both effort-independent — indicates genuine reduction in aerobic function, not effort limitation
- Intrinsic mitochondrial respiration reduced in Long COVID vs controls (qualitative alteration in mitochondrial function, not loss of mitochondrial content as in bed rest)
- No differences in capillarization or fibre cross-sectional area between Long COVID and controls, unlike bed-rest deconditioning
- GET/graded-exercise meta-analyses (Larun 2017, REGAIN 2024, Espinoza-Bravo 2023, Jimeno-Almazán 2022) include up to ~30% participants with comorbidities that would benefit from exercise
- Walitt et al. (2024) deep phenotyping supports physiological (autonomic dysfunction, CSF catecholamines, lower post-exercise cortisol) rather than psychological explanations of PEM, and peak measures did not correlate with effort preference
Conclusion:: Skeletal muscle alterations in Long COVID PEM are not explained by deconditioning; the phenotype differs fundamentally from bed-rest deconditioning, and submaximal effort-independent thresholds confirm a genuine aerobic deficit. Authors advocate caution regarding intense exercise while PEM thresholds remain ill-defined.
Limitations:: Commentary/reply (not primary data); no full age/sex/activity-matched control group (acknowledged by authors); limited to Long COVID PEM patients (~90% of Long COVID); GET/Larun critique based on trial-design confounds rather than new data.
Certainty Assessment::
- Quality:: Medium-High (primary data re-analysis + argument; reply to commentary)
- Sample:: Re-analysis of n=46 (25 LC + 21 HC) + matched step-count subset
- Replication:: Reinforces (Appelman et al. 2024) + (Charlton et al. 2026) (same cohort)
- Score:: 0.68

30 Fluge et al. 2016 — Impaired Pyruvate Dehydrogenase in ME/CFS

Full Citation:: Fluge Ø, Mella O, Bruland O, Risa K, Dyrstad SE, Alme K, Rekeland IG, Sapkota D, Røsland GV, Fosså A, et al. Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. JCI Insight. 2016;1(21):e89376. (Fluge et al. 2016)
DOI:: 10.1172/jci.insight.89376
PMID:: 28018972
Study Design:: Serum metabolomics (n=200 ME/CFS, 102 HC) + in vitro myoblast culture in patient serum + PBMC gene expression. Haukeland University Hospital, Bergen.
Key Findings::
- Specific reduction of amino acids fueling TCA cycle (mainly female patients); elevated 3-methylhistidine (protein catabolism) in males
- Functional PDH impairment via increased PDK1/2/4, SIRT4, PPARδ mRNA expression
- Myoblasts cultured in severe ME/CFS serum: increased mitochondrial respiration, excessive lactate secretion
- First serum-transfer-to-muscle-cell experiment in ME/CFS literature
Conclusion:: A circulating serum factor in ME/CFS impairs PDH function, shifting muscle metabolism toward glycolysis with compensatory mitochondrial hyperactivation. This is the methodological precursor to Mughal 2025.
Limitations:: Myoblasts (2D culture, not mature myotubes); serum factor identity unknown; moderate correlational design; PDH impairment inferred from amino acid patterns + mRNA, not direct enzymatic assay.
Certainty Assessment::
- Quality:: Medium-High (large n, multi-method, but 2D in vitro component)
- Sample:: n=302 (200 ME/CFS + 102 HC)
- Replication:: Partially replicated (Fernandez-Guerra 2021, Tomas 2017); PDH finding consistent with other metabolic studies
- Score:: 0.52

31 Charlton et al. 2025 — Skeletal Muscle Adaptations & PEM Review

Full Citation:: Charlton BT, Goulding RP, Jaspers RT, Appelman B, van Vugt M, Wüst RCI. Skeletal muscle adaptations and post-exertional malaise in long COVID. Trends in Endocrinology & Metabolism. 2025;36(7):614–622. (Charlton et al. 2025)
DOI:: 10.1016/j.tem.2024.11.008
PMID:: 39694730
Study Design:: Opinion/review article from Wüst lab (Amsterdam/Vrije Universiteit).
Key Findings::
- Mitochondrial dysfunction, endothelial abnormalities, glycolytic fiber type shift as main contributors to reduced exercise capacity in Long COVID
- Rapid skeletal muscle tissue damage and intramuscular immune cell infiltration contribute to PEM
- Metabolic shift toward glycolysis (away from OXPHOS) is central to post-exertional symptom worsening
- Bridges Appelman 2024 with emerging metabolic adaptation concept
Conclusion:: PEM pathophysiology involves multiple interacting mechanisms — mitochondrial, endothelial, and immunological — converging on skeletal muscle. Glycolytic shift is a maladaptive compensation, not a primary defect.
Limitations:: Opinion/review (no new data); Long COVID focus (may not fully generalize to ME/CFS without viral trigger).
Certainty Assessment::
- Quality:: Low-Medium (opinion piece with expert synthesis)
- Sample:: N/A (review)
- Replication:: N/A
- Score:: 0.36

32 Schreiner et al. 2020 — HHV-6 Reactivation & Mitochondrial Fragmentation in ME/CFS

Full Citation:: Schreiner P, Harrer T, Scheibenbogen C, Lamer S, Schlosser A, Naviaux RK, Prusty BK. Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in ME/CFS. Immunohorizons. 2020;4(4):201–215. (Schreiner et al. 2020)
DOI:: 10.4049/immunohorizons.2000006
PMID:: 32327453
Study Design:: In vitro — U2-OS cells with chromosomally integrated HHV-6A ± reactivation (trichostatin-A). Supernatant adoptive transfer to naive A549 cells. Adoptive transfer of serum from 10 ME/CFS patients to naive cells. Proteomics (pSILAC).
Key Findings::
- HHV-6 reactivation → mitochondrial fragmentation, PDH inhibition, 1-carbon metabolism induction, SOD2 suppression
- Supernatant adoptive transfer → antiviral state in naive cells preventing influenza/HSV-1 superinfection
- ME/CFS patient serum adoptive transfer → same mitochondrial fragmentation + antiviral state in naive cells
- Cell danger response model: antiviral protection at cost of compromised energy metabolism
Conclusion:: A serum-borne factor from ME/CFS patients — potentially HHV-6 miRNA or viral fragments — transfers a metabolic phenotype (mitochondrial fragmentation, PDH suppression, antiviral state) to healthy cells. This directly demonstrates that serum carries the metabolic pathology.
Limitations:: In vitro model (population weight 0.75 for patient serum transfer); n=10 ME/CFS sera (small); HHV-6 connection correlational in patient sera; U2-OS cells are osteosarcoma-derived, not muscle.
Certainty Assessment::
- Quality:: Medium (innovative design, but small n and cancer cell line)
- Sample:: n=10 ME/CFS sera
- Replication:: Consistent with Hennig 2022 (HHV-6 miR-aU14 causing DRP1 mitochondrial fragmentation)
- Score:: 0.41

33 Nilsson et al. 2020 — No Anti-Mitochondrial Antibodies in ME/CFS (NULL)

Full Citation:: Nilsson I, Palmer J, Apostolou E, Gottfries CG, Rizwan M, Dahle C, Rosén A. Metabolic Dysfunction in ME/CFS Not Due to Anti-Mitochondrial Antibodies. Frontiers in Medicine. 2020;7:108. (Nilsson et al. 2020)
DOI:: 10.3389/fmed.2020.00108
PMID:: 32296708
Study Design:: Cross-sectional antibody screening. n=161 ME/CFS, 15 PBC (positive control), 14 fibromyalgia, 29 MS, 44 healthy blood donors. Linköping University.
Key Findings::
- Only 1/161 ME/CFS positive for anti-PDC antibodies (vs 15/15 PBC patients)
- Anti-mitochondrial antibodies (inner/outer membrane) negative in ME/CFS
- Anti-cardiolipin antibody levels not significantly different from HC
Conclusion:: The metabolic/mitochondrial dysfunction observed in ME/CFS cannot be explained by circulating anti-mitochondrial autoantibodies. The serum factor is something else — cytokines, metabolites, miRNA, exosomes, or viral particles.
Limitations:: Only tested a limited panel of mitochondrial antigens; does not exclude antibodies against other mitochondrial epitopes; cross-sectional (cannot rule out transient autoantibody production).
Certainty Assessment::
- Quality:: Medium (well-powered null study, but limited antigen panel)
- Sample:: n=161 ME/CFS
- Replication:: Consistent with Germain 2025 (comprehensive autoantibody profiling null)
- Score:: 0.47

34 Fernández-Garibay et al. 2022 — Xeno-Free 3D Bioengineered Muscle Platform

Full Citation:: Fernández-Garibay X, Gómez-Florit M, Domingues RMA, Gomes ME, Fernández-Costa JM, Ramón-Azcón J. Xeno-free bioengineered human skeletal muscle tissue using human platelet lysate-based hydrogels. Biofabrication. 2022;14(4). (Fernández-Garibay et al. 2022)
DOI:: 10.1088/1758-5090/ac8dc8
PMID:: 36041422
Study Design:: Methodological — development and validation of xeno-free human platelet lysate (HUgel) hydrogel platform for 3D skeletal muscle tissue engineering. IBEC/Barcelona (Ramón-Azcón lab).
Key Findings::
- Human platelet lysate-based hydrogels with aldehyde-cellulose nanocrystals as xeno-free scaffold
- Tunable mechanical, structural, and biochemical properties for 3D stem cell culture
- Formation of highly aligned, long myotubes expressing sarcomeric proteins
- Electrical stimulation capability with non-invasive contractile force measurement
- This is the foundational platform technology used in Mughal 2025
Conclusion:: The IBEC group’s muscle-on-a-chip platform is validated for disease modeling and drug screening. The technology readiness supports Mughal 2025’s application to ME/CFS/LC sera.
Limitations:: Methodological paper (no disease application); hydrogel properties may not fully recapitulate native ECM; in vitro only.
Certainty Assessment::
- Quality:: High (rigorous engineering validation)
- Sample:: N/A (methodology)
- Replication:: Platform used in multiple subsequent papers (Tejedera-Villafranca 2023, Ruiz-Gutiérrez 2025, Mughal 2025)
- Score:: 0.28

35 Fernandez-Guerra et al. 2021 — PBMC Bioenergetics & PDH Proteomics in ME/CFS

Full Citation:: Fernandez-Guerra P, Gonzalez-Ebsen AC, Boonen SE, Courraud J, Gregersen N, Mehlsen J, Palmfeldt J, Olsen RKJ, Brinth LS. Bioenergetic and Proteomic Profiling of Immune Cells in ME/CFS Patients: An Exploratory Study. Biomolecules. 2021;11(7):961. (Fernandez-Guerra et al. 2021)
DOI:: 10.3390/biom11070961
PMID:: 34209852
Study Design:: Exploratory case-control. n=6 ME/CFS, age/gender-matched controls. PBMC bioenergetics (Seahorse extracellular flux analysis) + quantitative proteomics. Aarhus University.
Key Findings::
- PBMCs from ME/CFS patients showed significantly lower mitochondrial coupling efficiency
- Proteome alterations centred on pyruvate dehydrogenase (PDH) and coenzyme A metabolism
- Decreased capacity to provide adequate intracellular ATP levels
- Reinforces Fluge 2016 PDH impairment finding in immune cells (not just muscle)
Conclusion:: PDH/metabolic impairment in ME/CFS is systemic — detectable in circulating immune cells, not restricted to skeletal muscle. Supports the concept that a circulating factor affects multiple cell types.
Limitations:: Very small n=6; exploratory (not powered for firm conclusions); only PBMCs studied (not muscle); single time point.
Certainty Assessment::
- Quality:: Low (exploratory, n=6)
- Sample:: n=6 ME/CFS
- Replication:: Consistent with Fluge 2016 PDH findings
- Score:: 0.24

36 Cox et al. 2022 — EBV/HHV-6A dUTPases Drive TFH Differentiation and LLPC Generation in ME/CFS

Full Citation:: Cox BS, Alharshawi K, Mena-Palomo I, Lafuse WP, Ariza ME. EBV/HHV-6A dUTPases contribute to myalgic encephalomyelitis/chronic fatigue syndrome pathophysiology by enhancing TFH cell differentiation and extrafollicular activities. JCI Insight. 2022;7(11):e158193. (Cox et al. 2022)
DOI:: 10.1172/jci.insight.158193
PMID:: 35482424
Study Design:: Cross-sectional human cohort (ME/CFS vs controls) + in vitro mechanistic + in vivo mouse model
Key Findings::
- ME/CFS patients have elevated activin A and IL-21 serum levels correlating with antibodies against EBV/HHV-6 dUTPases
- IL-21 elevated without concomitant CXCL13 increase → impaired germinal center function in ME/CFS
- ME/CFS serum sufficient to drive TFH cell differentiation via activin A-dependent mechanism
- EBV dUTPase induced marginal zone B cell and invariant NKT-FH cell expansion in mouse spleen
- Viral dUTPases strongly induced activin A secretion in vitro
Conclusion:: EBV and HHV-6A dUTPases dysregulate germinal center activity and promote extrafollicular antibody responses in ME/CFS, potentially generating pathogenic long-lived plasma cells (LLPCs) via a TFH/activin A/IL-21 axis.
Relevance to Daratumumab:: Provides the most direct mechanistic bridge from viral trigger → aberrant TFH activity → LLPC generation in ME/CFS. Explains why plasma-cell targeting (daratumumab, anti-CD38) could succeed where B-cell targeting (rituximab, anti-CD20) failed: the pathogenic autoantibody-producing cells may be CD20-negative, CD38-positive LLPCs generated during a dysregulated germinal center response. The elevated IL-21 without CXCL13 pattern suggests impaired GC function despite ongoing TFH differentiation — a signature of extrafollicular autoantibody production.
Limitations:: Cohort size not specified in abstract for human arm; single-timepoint cross-sectional design; mouse model used EBV dUTPase only (not HHV-6A); direct causal link from dUTPase→LLPC generation not experimentally proven.
Certainty Assessment::
- Quality:: High (JCI Insight; multi-level evidence: human serum, in vitro, mouse)
- Sample:: Human cohort (size unspecified in abstract) + in vitro + mouse
- Replication:: Partially supported by Williams/Cox/Ariza 2025 (heightened anti-dUTPase IgG in post-infectious ME/CFS); no independent replication of TFH/activin A axis
- Score:: 0.65

37 Ray et al. 2026 — NK Cell Dysregulation Defines Long COVID Symptoms

Full Citation:: Ray U, Schulze Selting A, Perera RP, Yang Z, Lysenkov V, Göpel S, Bitzer M, Salker MS, Ossowski S, Riess O, Casadei N, Singh Y. Dysregulated NK-cell gene expression defines the enduring symptoms of long COVID-19. Frontiers in Immunology. 2026;17:1720551. (Ray et al. 2026)
DOI:: 10.3389/fimmu.2026.1720551
PMID:: 41878441
Study Design:: Cross-sectional multi-omics: plasma antibody/cytokine profiling (n=94 LTCS, 24 CONV, 66 HC), 14-color flow cytometry (n=23/6/9), scRNA-seq PBMCs (n=32/6/8)
Key Findings::
- LTCS patients had elevated anti-SARS-CoV-2 IgG titers but significantly REDUCED systemic cytokines (IFN-γ, TNF-α, IL-6, IL-10)
- Flow cytometry: marked depletion of CD56+CD16+ NK cells and CD56+CD3+ NKT cells
- scRNA-seq confirmed NK type I cell loss with upregulation of PDCD4, CHD1, CXCR4, SLC7A5 and downregulation of TGFBR3, RIPOR2, MBNL1
- Gene set enrichment: activation of circadian/translational programs; suppression of olfactory, neurotransmitter receptor, and GABA-gated ion-channel pathways
- Functional assays validated reduced NK-cell inflammatory capacity
Conclusion:: Long COVID is characterized by systemic cytokine attenuation and quantitative/functional NK-cell deficit coupled to neurosensory pathway suppression, identifying an NK-centric neuroimmune axis.
Relevance to Daratumumab:: Fluge 2025 identified low baseline NK-cell count as a significant predictor of NON-response to daratumumab in ME/CFS. Daratumumab itself depletes CD38+ NK cells (on-target effect). This study demonstrates that post-viral fatigue syndromes feature pre-existing NK depletion and dysfunction. If daratumumab further depletes already-compromised NK cells, this could paradoxically worsen immune surveillance — a potential mechanism explaining the non-responder pattern.
Limitations:: Cross-sectional (no longitudinal data on NK recovery); long COVID only (not ME/CFS cohort); no mechanistic confirmation of NK→symptom causality.
Certainty Assessment::
- Quality:: High (multi-omic design with orthogonal validation; Frontiers in Immunology, peer-reviewed)
- Sample:: n=94 LTCS + 24 CONV + 66 HC (antibody/cytokine); subset for deep phenotyping
- Replication:: Consistent with prior NK depletion findings in ME/CFS (Baraniuk 2024 meta-analysis); no direct replication of scRNA-seq signature yet
- Score:: 0.45 (discounted for Long COVID population, not ME/CFS)

38 Drew 2026 — Hibernation-Inspired Innovations in Biomedicine

Full Citation:: Drew KL. Hibernation-Inspired Innovations in Biomedicine: Addressing Aging, Chronic Diseases, and Critical Care. Canadian Journal of Zoology. 2026;104. (Drew 2026)
DOI:: 10.1139/cjz-2025-0055
Key Findings::
- Interbout arousals provide insights into tolerance of rapid rewarming and reperfusion
- Hibernators resist muscle atrophy, bone loss, and neuronal damage during prolonged inactivity
- Reversible metabolic suppression, insulin resistance, and adaptive anorexia inform obesity/diabetes research
- Temperature-independent neuroprotection and nitrogen recycling offer translational opportunities
Conclusion:: Hibernation biology represents an underexploited drug-discovery resource. Interbout arousal — a physiological, reversible circuit-state-reset — is conserved across mammals.
Limitations:: Review; author (KLD) has financial interest in Be Cool Pharmaceutics. Translational path from hibernator biology to human therapy is unvalidated.
Certainty Assessment::
- Quality:: Medium (review, peer-reviewed, COI disclosed)
- Sample:: n/a (review)
- Replication:: n/a
- Score:: 0.35

39 Markussen et al. 2024 — c-fos in Choroid Plexus at Spontaneous Arousal

Full Citation:: Markussen FAF, Cázarez-Márquez F, Melum VJ, Hazlerigg DG, Wood SH. c-fos induction in the choroid plexus, tanycytes and pars tuberalis is an early indicator of spontaneous arousal from torpor in a deep hibernator. Journal of Experimental Biology. 2024;227(10):jeb247224. (Markussen et al. 2024)
DOI:: 10.1242/jeb.247224
Key Findings::
- Non-neuronal sites (choroid plexus, pars tuberalis, third ventricle tanycytes) show peak c-fos at arousal initiation
- Dorsomedial hypothalamus active during torpor entry but NOT at earliest arousal stages — nor is the preoptic area
- Suggests metabolic feedback from blood/CSF factors initiates spontaneous arousal, not only hypothalamic thermoregulation
Conclusion:: Arousal initiation from torpor involves non-neuronal metabolic sensing in brain barrier structures. This is distinct from the hypothalamic EP3R switch in torpor entry.
Limitations:: Rodent study (golden hamster); c-fos is a proxy for neural activity; causality not established.
Certainty Assessment::
- Quality:: High (Journal of Experimental Biology, high-resolution multi-parameter monitoring)
- Sample:: Animal (hamster, n not specified)
- Replication:: Single study
- Score:: 0.34

40 Hunstiger et al. 2023 — Non-Shivering Thermogenesis in Arctic Ground Squirrels

Full Citation:: Hunstiger M, Johannsen MM, Oliver SR. Non-shivering thermogenesis is differentially regulated during the hibernation season in Arctic ground squirrels. Frontiers in Physiology. 2023;14:1207529. (Hunstiger, Johannsen, and Oliver 2023)
DOI:: 10.3389/fphys.2023.1207529
Key Findings::
- BAT UCP1 peaks in winter and tapers after terminal arousal — primary thermogenic source for interbout arousal
- Muscular NST (SERCA1a/2a, sarcolipin) shows opposite pattern: depressed in late hibernation, rebounds after terminal arousal
- White adipose tissue shows no UCP1 expression
- Differential timing indicates distinct NST functions in maintaining thermogenesis
Conclusion:: BAT UCP1 is the primary thermogenic driver of interbout arousal. Muscular NST plays a role in post-hibernation recovery, not in arousal itself.
Limitations:: Animal study; protein expression (not direct thermogenesis measurement); seasonal sampling may confound date-of-arousal effects.
Certainty Assessment::
- Quality:: Medium (Frontiers in Physiology, wild-caught animals, seasonal longitudinal design)
- Sample:: Animal (Arctic ground squirrels, seasonal n)
- Replication:: Consistent with prior UCP1 literature
- Score:: 0.32

41 González-Riaño et al. 2025 — Brain Lipidomics of Hibernating Syrian Hamsters

Full Citation:: González-Riaño C, León-Espinosa G, Regalado-Reyes M, García A, DeFelipe J, Barbas C. Advanced lipidomics using UHPLC-ESI-QTOF-MS/MS reveals novel lipids in hibernating Syrian hamsters. Journal of Chromatography A. 2025;1743:465692. (González-Riaño et al. 2025)
DOI:: 10.1016/j.chroma.2025.465692
Key Findings::
- 377 lipid species annotated across late torpor, arousal, and euthermic stages
- PMeOH (methylated lysophosphatidic acid) elevated during torpor — cell survival signalling
- Decreased phosphatidic acid with increased DAG implies PKC signalling shift
- MGDG lipids elevated in torpor suggest neuroprotection via oligodendrocyte function
Conclusion:: Torpor induces specific brain lipidome remodelling consistent with membrane fluidity maintenance and oxidative stress protection. The DAG↑/PA↓ shift is a candidate arousal-preparatory signal.
Limitations:: Descriptive lipidomics (no functional validation); single species (Syrian hamster); small group sizes for cross-stage comparison.
Certainty Assessment::
- Quality:: Medium (Journal of Chromatography A, advanced MS/MS methodology)
- Sample:: Animal (hamster, n per stage unclear)
- Replication:: Single study
- Score:: 0.31

42 Wang et al. 2026 — T2T Genome: Arachidonic Acid in Hibernation Lipid Metabolism

Full Citation:: Wang L, Chen P, Gao Q, et al. A telomere-to-telomere genome reveals arachidonic acid as a key regulator of hepatic lipid metabolism during hibernation. Communications Biology. 2026. (Wang et al. 2026)
DOI:: 10.1038/s42003-026-10625-x
Key Findings::
- First T2T genome of a hibernating mammal (Daurian ground squirrel, 2.69 Gb, 19 chromosomes)
- Comparative genomics of 17 species: arachidonic acid pathway enriched in hibernator-expanded gene families
- Multi-omics (transcriptomic + metabolomic) across 4 hibernation stages confirmed arachidonic acid (20:4 n-6) as key regulator
- In-vitro: arachidonic acid interacts with PPARα and TRPV channels, triggering Ca2+ signalling and lipid metabolic enzyme expression
Conclusion:: Arachidonic acid is a key lipid signal in hibernation metabolic regulation, operating through PPARα/TRPV-Ca2+ axis. This connects directly to the eicosanoid/PnS prostaglandin arousal-cascade hypothesis.
Limitations:: Single organ (liver); in-vitro validation uses primary hepatocytes (not in vivo); T2T assembly for one individual.
Certainty Assessment::
- Quality:: High (Communications Biology, Nature portfolio, multi-omics + in-vitro)
- Sample:: Animal (Daurian ground squirrel) + in-vitro hepatocytes
- Replication:: Single study (first T2T for this species)
- Score:: 0.35

43 Shimaoka et al. 2018 — A1 Adenosine Receptor Hypothermia in Non-Hibernators

Full Citation:: Shimaoka H, Kawaguchi T, Morikawa K, et al. Induction of hibernation-like hypothermia by central activation of the A1 adenosine receptor in a non-hibernator, the rat. Journal of Physiological Sciences. 2018;68(4):425–430. (Shimaoka et al. 2018)
DOI:: 10.1007/s12576-017-0543-y
Key Findings::
- Intracerebroventricular CHA (A1AR agonist) induces deep hypothermia (under 20 deg C) with maintained sinus rhythm in non-hibernating rats
- Forced cooling of anesthetized rats without A1AR activation causes cardiac arrest
- Pentobarbital abolished the protective rhythm effect — implies active, anaesthesia-sensitive mechanism
Conclusion:: Central A1AR activation is a conserved torpor-entry signal that can be pharmacologically induced across species. This is the strongest translational bridge from hibernation biology to human hypometabolic-state induction.
Limitations:: Rat study (non-hibernator but still rodent); single A1 agonist (CHA); hypothermia, not full torpor phenotype; no metabolic rate measurements.
Certainty Assessment::
- Quality:: High (clear experimental design, cardiac monitoring, cross-species relevance)
- Sample:: Animal (rat, n per group unclear)
- Replication:: Consistent with later Uchino 2024 (torpor-tagged neuron activation by A1 agonist)
- Score:: 0.40

44 Wu and Storey 2021 — mTOR Signaling in Metabolic Stress Adaptation

Full Citation:: Wu CW, Storey KB. mTOR Signaling in Metabolic Stress Adaptation. Biomolecules. 2021;11(5):681. (Wu and Storey 2021)
DOI:: 10.3390/biom11050681
Key Findings::
- mTORC1 suppression is a conserved feature of metabolic depression across hibernation, estivation, anoxia tolerance, and dauer diapause
- mTOR reactivation accompanies arousal from torpor
- mTOR exhibits stressor-dependent regulatory patterns across diverse species
Conclusion:: mTORC1 is a central metabolic switch for torpor entry (suppressed) and arousal (reactivated). This is an evolutionary homolog of the AMPK/mTOR energy-state switch in the Komaroff-Dantzer circuit model.
Limitations:: Review (no primary data); broad scope across multiple stress states may obscure hibernation-specific mechanisms.
Certainty Assessment::
- Quality:: Medium (Biomolecules, comprehensive review, Storey lab is a leading hibernation biochemistry group)
- Sample:: n/a (review)
- Replication:: n/a
- Score:: 0.33

45 Jobava et al. 2021 — Adaptive Translational Pausing in Severe Stress

Full Citation:: Jobava R, Mao Y, Guan BJ, et al. Adaptive translational pausing is a hallmark of the cellular response to severe environmental stress. Molecular Cell. 2021;81(20):4191–4208.e8. (Jobava et al. 2021)
DOI:: 10.1016/j.molcel.2021.09.029
Key Findings::
- Severe hyperosmotic stress induces a transient hibernation-like state (adaptive pausing response, APR) in mammalian cells
- APR coordinates ATP conservation via mitochondrial fragmentation and widespread translational pausing at initiation codons
- mRNAs remain poised to resume translation upon recovery via ISR signalling
- Recovery involves cell cycle progression, growth resumption, and mitochondrial reversal
Conclusion:: Non-hibernating mammalian cells possess a latent hibernation-like metabolic shutdown program. This provides a cellular mechanism model for the ME/CFS low-energy state — not a passive failure but an active, coordinated survival program.
Limitations:: In-vitro (hyperosmotic stress model); not a hibernation organism study; extrapolation from acute stress to chronic illness is speculative.
Certainty Assessment::
- Quality:: High (Molecular Cell, rigorous mechanistic design)
- Sample:: In-vitro mammalian cells
- Replication:: Independent labs; translational pausing mechanism verified
- Score:: 0.47

46 Blanco et al. 2024 — Primate Hibernation: Captive Dwarf Lemurs

Full Citation:: Blanco MB, Greene LK, Welser KH, Ehmke EE, Yoder AD, Klopfer PH. Primate hibernation: The past, present, and promise of captive dwarf lemurs. Annals of the New York Academy of Sciences. 2024;1540(1):178–190. (Blanco et al. 2024)
DOI:: 10.1111/nyas.15206
Key Findings::
- Dwarf lemurs (Cheirogaleus spp.) are the only obligate primate hibernators
- Duke Lemur Center successfully induced hibernation in captivity after decades of failure
- Stable cold (13 deg C) with food: shallower torpor bouts, modified gut microbiome
- Fluctuating temperatures: passive daily rewarming, altered fat depletion, reduced oxidative stress
Conclusion:: Primate hibernation is achievable and environmentally manipulable — the best translational bridge from hibernation biology to human applications. The primate torpor-arousal cycle is the closest available model for human circuit-state transitions.
Limitations:: Review/colony report; small colony; endangered species limits experimental manipulations; no molecular-level data in this review.
Certainty Assessment::
- Quality:: Medium (Annals of NYAS, captive colony report, preliminary data)
- Sample:: Animal (captive dwarf lemurs, small n)
- Replication:: n/a (unique colony)
- Score:: 0.34

47 Dias et al. 2021 — Stem Cell Dormancy and Hibernation

Full Citation:: Dias IB, Bouma HR, Henning RH. Unraveling the Big Sleep: Molecular Aspects of Stem Cell Dormancy and Hibernation. Frontiers in Physiology. 2021;12:624950. (Dias, Bouma, and Henning 2021)
DOI:: 10.3389/fphys.2021.624950
Key Findings::
- Shared molecular factors between hematopoietic stem cell quiescence and torpor: reversible cell cycle inhibition, glucose-to-FAO shift, mitochondrial downregulation, HIF-1α changes, mTOR suppression, autophagy, radiation resistance
- Similarity is remarkable despite different cell populations (proliferating stem cells vs. terminally differentiated cells in torpor)
Conclusion:: Cellular dormancy programs are deeply conserved between stem cell biology and hibernation physiology. The mTOR-HIF-1α-autophagy axis is a convergent energy-state regulator.
Limitations:: Review (no primary data); comparison across very different biological contexts may obscure mechanistic differences.
Certainty Assessment::
- Quality:: Medium (Frontiers in Physiology, clear comparative framework)
- Sample:: n/a (review)
- Replication:: n/a
- Score:: 0.34

48 Fu et al. 2021 — Hibernation Brain Transcriptome (13-Lined Ground Squirrel)

Full Citation:: Fu R, Gillen AE, Grabek KR, et al. Dynamic RNA Regulation in the Brain Underlies Physiological Plasticity in a Hibernating Mammal. Frontiers in Physiology. 2021;11:624677. (Fu et al. 2021)
DOI:: 10.3389/fphys.2020.624677
Key Findings::
- 6,505 hibernation-related differentially expressed/processed transcripts across three brain regions
- First deconvolution of seasonal vs. temperature-dependent effects on brain transcriptome
- Regulatory network of RNA binding proteins dynamic in hibernation
- Evidence for regulated transcription and RNA turnover (not just passive temperature effects)
Conclusion:: Hibernation involves active, regulated transcriptomic programming in the brain, not passive cold-induced suppression. This dataset is the primary transcriptomic resource for benchmarking ME/CFS brain expression patterns against a natural hypometabolic state.
Limitations:: Animal study (ground squirrel); bulk tissue RNA-seq (not single-cell); COI: KG at Fauna Bio, SM/CB on SAB.
Certainty Assessment::
- Quality:: Medium-High (Frontiers in Physiology, enhanced genome assembly, squirrelBox tool)
- Sample:: Animal (13-lined ground squirrel, n per condition specified)
- Replication:: Consistent with prior hibernation transcriptome studies
- Score:: 0.32

49 Duffy et al. 2022 — Arousal Increases Oxidative Damage

Full Citation:: Duffy BM, Staples JF, Tessier SN. Arousal from Torpor Increases Oxidative Damage in the Hibernating Thirteen-Lined Ground Squirrel. Physiological and Biochemical Zoology. 2022;95(3):229–238. (Duffy, Staples, and Tessier 2022)
DOI:: 10.1086/719931
Key Findings::
- Interbout arousal increases oxidative damage (protein carbonylation, lipid peroxidation) in ground squirrel tissues
- The arousal process — while essential for metabolic homeostasis — carries a measurable oxidative cost
Conclusion:: Counterbalances the narrative that interbout arousal is a benign, purely restorative process. Pharmacological arousal from a torpor-like state in ME/CFS could impose oxidative stress if the protective adaptations of natural hibernators are not also engaged.
Limitations:: Animal study; single species; oxidative markers are proxies (not functional endpoints).
Certainty Assessment::
- Quality:: Medium (Physiological and Biochemical Zoology, clear hypothesis test)
- Sample:: Animal (13-lined ground squirrel)
- Replication:: Consistent with general ROS biology in ischemia-reperfusion; specific to hibernation context
- Score:: 0.32

References

Alten, Rieke, Amy Grahn, Robert J Holt, Patricia Rice, and Frank Buttgereit. 2015. “Delayed-Release Prednisone Improves Fatigue and Health-Related Quality of Life: Findings from the CAPRA-2 Double-Blind Randomised Study in Rheumatoid Arthritis.” RMD Open 1 (1): e000134. https://doi.org/10.1136/rmdopen-2015-000134.

Appelman, Brent, Braeden T. Charlton, Richie P. Goulding, Tom J. Kerkhoff, Ellen A. Breedveld, Wendy Noort, Carla Offringa, et al. 2024. “Muscle Abnormalities Worsen After Post-Exertional Malaise in Long COVID.” Nature Communications 15: 17. https://doi.org/10.1038/s41467-023-44432-3.

Appelman, Brent, Braeden T. Charlton, Richie P. Goulding, Tom J. Kerkhoff, Ellen A. Breedveld, Wendy Noort, Carla Offringa, et al. 2025. “Reply: Muscle Abnormalities in Long COVID.” Nature Communications 16: 1491. https://doi.org/10.1038/s41467-025-56431-7.

Augustin, M, L Picard, D Rauschning, E Zenev, E Pracht, U S de Silva, F Heyn, et al. 2026. “Persistent Gut-Immune Axis Dysregulation in Long-Term Post-COVID Syndrome: Insights from a Prospective, Observational, Cross-Sectional Case-Control Study.” Mucosal Immunology 19 (3): 100328. https://doi.org/10.1016/j.mucimm.2026.03.002.

Azcue, N, A Prada, R Del Pino, M Acera, T Fernandez-Valle, N Ayo-Mentxakatorre, T Perez-Concha, et al. 2026. “Involvement of Autoantibodies Against G Protein-Coupled Receptors in Post-COVID Condition and Chronic Fatigue Syndrome.” Scientific Reports 16 (1): 20609. https://doi.org/10.1038/s41598-026-49131-9.

Baraniuk, J N, N Eaton-Fitch, and S Marshall-Gradisnik. 2024. “Meta-Analysis of Natural Killer Cell Cytotoxicity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Frontiers in Immunology 15: 1440643. https://doi.org/10.3389/fimmu.2024.1440643.

Blanco, Marina B, Lydia K Greene, Kayla H Welser, Erin E Ehmke, Anne D Yoder, and Peter H Klopfer. 2024. “Primate Hibernation: The Past, Present, and Promise of Captive Dwarf Lemurs.” Annals of the New York Academy of Sciences 1540 (1): 178–90. https://doi.org/10.1111/nyas.15206.

Brigo, Natascha, Wolfram Mayr, Maja Taenzer, Judith Löffler-Ragg, Andrea Schroll, Sabine Engl, Burkhard Schütz, et al. 2025. “Concentrations of Uremic Bacterial Metabolites in Patients with Post-COVID-19 Syndrome.” Frontiers in Cellular and Infection Microbiology 15: 1582972. https://doi.org/10.3389/fcimb.2025.1582972.

Charlton, Braeden T., Richie P. Goulding, Richard T. Jaspers, Brent Appelman, Michèle van Vugt, and Rob C. I. Wüst. 2025. “Skeletal Muscle Adaptations and Post-Exertional Malaise in Long COVID.” Trends in Endocrinology & Metabolism 36 (7): 614–22. https://doi.org/10.1016/j.tem.2024.11.008.

Charlton, Braeden T., Anouk Slaghekke, Brent Appelman, Moritz Eggelbusch, Jelle Y. Huijts, Wendy Noort, Paul W. Hendrickse, et al. 2026. “Skeletal Muscle Properties in Long COVID and ME/CFS Differ from Those Induced by Bed Rest.” Nature Communications. https://doi.org/10.1038/s41467-026-75725-y.

Cox, Brandon S, Khaled Alharshawi, Irene Mena-Palomo, William P Lafuse, and Maria Eugenia Ariza. 2022. “EBV/HHV-6A dUTPases Contribute to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Pathophysiology by Enhancing TFH Cell Differentiation and Extrafollicular Activities.” JCI Insight 7 (11): e158193. https://doi.org/10.1172/jci.insight.158193.

Cutolo, Maurizio. 2019. “Circadian Rhythms and Rheumatoid Arthritis.” Joint Bone Spine 86 (3): 327–33. https://doi.org/10.1016/j.jbspin.2018.09.003.

Dantzer, Robert. 2001. “Cytokine-Induced Sickness Behavior: Mechanisms and Implications.” Ann NY Acad Sci 933: 222–34. https://doi.org/10.1111/j.1749-6632.2001.tb05827.x.

Dias, Isabel B, Hjalmar R Bouma, and Robert H Henning. 2021. “Unraveling the Big Sleep: Molecular Aspects of Stem Cell Dormancy and Hibernation.” Frontiers in Physiology 12: 624950. https://doi.org/10.3389/fphys.2021.624950.

Drew, Kelly L. 2026. “Hibernation-Inspired Innovations in Biomedicine: Addressing Aging, Chronic Diseases, and Critical Care.” Canadian Journal of Zoology 104: 10.1139/cjz-2025-0055. https://doi.org/10.1139/cjz-2025-0055.

Duffy, Brynne M, James F Staples, and Shannon N Tessier. 2022. “Arousal from Torpor Increases Oxidative Damage in the Hibernating Thirteen-Lined Ground Squirrel (Ictidomys Tridecemlineatus).” Physiological and Biochemical Zoology 95 (3): 229–38. https://doi.org/10.1086/719931.

Fernández-Garibay, Xavi, Manuel Gómez-Florit, Rui M. A. Domingues, Manuela E. Gomes, Juan M. Fernández-Costa, and Javier Ramón-Azcón. 2022. “Xeno-Free Bioengineered Human Skeletal Muscle Tissue Using Human Platelet Lysate-Based Hydrogels.” Biofabrication 14 (4). https://doi.org/10.1088/1758-5090/ac8dc8.

Fernandez-Guerra, Paula, Ana C. Gonzalez-Ebsen, Susanne E. Boonen, Julie Courraud, Niels Gregersen, Jesper Mehlsen, Johan Palmfeldt, Rikke K. J. Olsen, and Louise S. Brinth. 2021. “Bioenergetic and Proteomic Profiling of Immune Cells in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients: An Exploratory Study.” Biomolecules 11 (7): 961. https://doi.org/10.3390/biom11070961.

Fluge, Øystein, Olav Mella, Ove Bruland, Kristin Risa, Sissel E. Dyrstad, Kine Alme, Ingrid G. Rekeland, et al. 2016. “Metabolic Profiling Indicates Impaired Pyruvate Dehydrogenase Function in Myalgic Encephalopathy/Chronic Fatigue Syndrome.” JCI Insight 1 (21): e89376. https://doi.org/10.1172/jci.insight.89376.

Fu, Rui, Austin E Gillen, Katharine R Grabek, Kent A Riemondy, L Elaine Epperson, Carlos D Bustamante, Jay R Hesselberth, and Sandra L Martin. 2021. “Dynamic RNA Regulation in the Brain Underlies Physiological Plasticity in a Hibernating Mammal.” Frontiers in Physiology 11: 624677. https://doi.org/10.3389/fphys.2020.624677.

Galbo, Henrik, and Lisbeth Kall. 2016. “Circadian Variations in Clinical Symptoms and Concentrations of Inflammatory Cytokines, Melatonin, and Cortisol in Polymyalgia Rheumatica Before and During Prednisolone Treatment: A Controlled, Observational, Clinical Experimental Study.” Arthritis Research & Therapy 18: 174. https://doi.org/10.1186/s13075-016-1072-4.

González-Riaño, Carolina, Gonzalo León-Espinosa, Mamen Regalado-Reyes, Antonia García, Javier DeFelipe, and Coral Barbas. 2025. “Advanced Lipidomics Using UHPLC-ESI-QTOF-MS/MS Reveals Novel Lipids in Hibernating Syrian Hamsters.” Journal of Chromatography A 1743: 465692. https://doi.org/10.1016/j.chroma.2025.465692.

Guarnotta, Valentina, Roberta Amodei, and Carla Giordano. 2021. “Metabolic Comorbidities of Adrenal Insufficiency: Focus on Steroid Replacement Therapy and Chronopharmacology.” Current Opinion in Pharmacology 60: 123–32. https://doi.org/10.1016/j.coph.2021.07.003.

Hermida, Ramón C, Michael H Smolensky, Howard Balan, Richard J Castriotta, Juan J Crespo, Yaron Dagan, Sherine El-Toukhy, et al. 2021. “Guidelines for the Design and Conduct of Human Clinical Trials on Ingestion-Time Differences — Chronopharmacology and Chronotherapy — of Hypertension Medications.” Chronobiology International 38 (1): 1–26. https://doi.org/10.1080/07420528.2020.1850468.

Hrvatin, S, S Sun, O F Wilcox, H Yao, A J Lavin-Peter, M Cicconet, E G Assad, et al. 2020. “Neurons That Regulate Mouse Torpor.” Nature 583 (7814): 115–21. https://doi.org/10.1038/s41586-020-2387-5.

Hunstiger, Moriah, Maren M Johannsen, and Shawn R Oliver. 2023. “Non-Shivering Thermogenesis Is Differentially Regulated During the Hibernation Season in Arctic Ground Squirrels.” Frontiers in Physiology 14: 1207529. https://doi.org/10.3389/fphys.2023.1207529.

Jobava, Raul, Yuanhui Mao, Bo-Jhih Guan, Dawei Hu, Dawid Krokowski, Chih-Wei Chen, Xing-En Shu, et al. 2021. “Adaptive Translational Pausing Is a Hallmark of the Cellular Response to Severe Environmental Stress.” Molecular Cell 81 (20): 4191–4208.e8. https://doi.org/10.1016/j.molcel.2021.09.029.

Komaroff, Anthony L, and Robert Dantzer. 2025. “Causes of Symptoms and Symptom Persistence in Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Cell Reports Medicine 6 (8): 102259. https://doi.org/10.1016/j.xcrm.2025.102259.

Kuring, J. K., J. L. Mathias, L. Ward, and G. Tachas. 2023. “Inflammatory Markers in Persons with Clinically-Significant Depression, Anxiety or PTSD: A Systematic Review and Meta-Analysis.” Journal of Psychiatric Research 168: 279–92. https://doi.org/10.1016/j.jpsychires.2023.10.009.

———. 2026. “Inflammatory Markers Associated with Dementia: A Systematic Review and Meta-Analysis.” Journal of Psychiatric Research 197: 26–40. https://doi.org/10.1016/j.jpsychires.2026.02.044.

Lévi, Francis A, Alper Okyar, Eva Hadadi, Pasquale F Innominato, and Annabelle Ballesta. 2024. “Circadian Regulation of Drug Responses: Toward Sex-Specific and Personalized Chronotherapy.” Annual Review of Pharmacology and Toxicology 64: 89–114. https://doi.org/10.1146/annurev-pharmtox-051920-095416.

Livieratos, Achilleas, Steven W Lockley, and Sotirios Tsiodras. 2025. “Post Infectious Fatigue and Circadian Rhythm Disruption in long-COVID and Other Infections: A Need for Further Research.” EClinicalMedicine 80: 103073. https://doi.org/10.1016/j.eclinm.2025.103073.

Machado, N L S, N Lynch, L H A Costa, D Melville, H Kucukdereli, S Kaur, et al. 2025. “Preoptic EP3R Neurons Constitute a Two-Way Switch for Fever and Torpor.” Nature 644 (8076): 463–72. https://doi.org/10.1038/s41586-025-09056-1.

Malatji, Bontle G., Helgard Meyer, Shayne Mason, Udo F. H. Engelke, Ron A. Wevers, Mari van Reenen, and Carolus J. Reinecke. 2017. “A Diagnostic Biomarker Profile for Fibromyalgia Syndrome Based on an NMR Metabolomics Study of Selected Patients and Controls.” BMC Neurology 17 (1): 88. https://doi.org/10.1186/s12883-017-0863-9.

Markussen, Fredrik Andreas Falkenberg, Fernando Cázarez-Márquez, Vebjørn Jacobsen Melum, David G Hazlerigg, and Shona H Wood. 2024. “C-Fos Induction in the Choroid Plexus, Tanycytes and Pars Tuberalis Is an Early Indicator of Spontaneous Arousal from Torpor in a Deep Hibernator.” Journal of Experimental Biology 227 (10): jeb247224. https://doi.org/10.1242/jeb.247224.

Mughal, Sheeza, Félix Andújar-Sánchez, Maria Sabater-Arcis, Glòria Garrabou, Joaquim Fernández-Solà, Jose Alegre-Martin, Ramon Sanmartin-Sentañes, et al. 2025. “Metabolic Adaptation and Fragility in Healthy 3D in Vitro Skeletal Muscle Tissues Exposed to Chronic Fatigue Syndrome and Long COVID-19 Sera.” Biofabrication 17 (4). https://doi.org/10.1088/1758-5090/adf66c.

Nilsson, Ida, Jeremy Palmer, Eirini Apostolou, Carl G. Gottfries, Muhammad Rizwan, Charlotte Dahle, and Anders Rosén. 2020. “Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Not Due to Anti-Mitochondrial Antibodies.” Frontiers in Medicine 7: 108. https://doi.org/10.3389/fmed.2020.00108.

Ohdo, Shigehiro. 2021. “Chrono-Drug Discovery and Development Based on Circadian Rhythm of Molecular, Cellular and Organ Level.” Biological & Pharmaceutical Bulletin 44 (6): 747–61. https://doi.org/10.1248/bpb.b21-00277.

Okyar, Alper, Dilek Ozturk Civelek, Yasemin Kubra Akyel, Saliha Surme, Zeliha Pala Kara, and Ibrahim Halil Kavakli. 2024. “The Role of the Circadian Timing System on Drug Metabolism and Detoxification: An Update.” Expert Opinion on Drug Metabolism & Toxicology 20 (6): 503–17. https://doi.org/10.1080/17425255.2024.2356167.

Ray, Urvi, Antje Schulze Selting, Roshan Priyarangana Perera, Zhiqi Yang, Vladislav Lysenkov, Siri Göpel, Michael Bitzer, et al. 2026. “Dysregulated NK-Cell Gene Expression Defines the Enduring Symptoms of Long COVID-19.” Frontiers in Immunology 17: 1720551. https://doi.org/10.3389/fimmu.2026.1720551.

Schreiner, Philipp, Thomas Harrer, Carmen Scheibenbogen, Stephanie Lamer, Andreas Schlosser, Robert K. Naviaux, and Bhupesh K. Prusty. 2020. “Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Immunohorizons 4 (4): 201–15. https://doi.org/10.4049/immunohorizons.2000006.

Shimaoka, Haruka, Tomoya Kawaguchi, Kana Morikawa, Yuuki Sano, Kiyotada Naitou, Hiroyuki Nakamori, Takahiko Shiina, and Yasutake Shimizu. 2018. “Induction of Hibernation-Like Hypothermia by Central Activation of the A1 Adenosine Receptor in a Non-Hibernator, the Rat.” Journal of Physiological Sciences 68 (4): 425–30. https://doi.org/10.1007/s12576-017-0543-y.

Sommen, S L, S Segtnan, J Selvakumar, L B Havdal, T Stiansen-Sonerud, J Gjerstad, S Mjaaland, et al. 2026. “Long COVID: Deep Single-Cell Immunophenotyping and Machine Learning Reveal a General Signature for Fatigue.” Journal of Translational Medicine 24 (1): 736. https://doi.org/10.1186/s12967-026-08149-3.

Strawbridge, Rebecca, Maria Laura Sartor, Fiona Scott, and Anthony J Cleare. 2019. “Inflammatory Proteins Are Altered in Chronic Fatigue Syndrome–a Systematic Review and Meta-Analysis.” Neuroscience and Biobehavioral Reviews 107: 69–83. https://doi.org/10.1016/j.neubiorev.2019.08.011.

Tuomaala, J, M Saraste, E Smith, M Kuusi, E Westerberg, E Honkonen, R Kargar, et al. 2026. “Association Between Post-COVID-19 Neuropsychiatric Symptoms and Persistent Glial Activation in the Limbic System: A TSPO PET Study.” Journal of Neurology 273 (5): 298. https://doi.org/10.1007/s00415-026-13842-w.

Wang, Lu, Peng Chen, Qian Gao, Ying Men, Quanyuan Yun, Qiang Zhang, Xin Xing, et al. 2026. “A Telomere-to-Telomere Genome Reveals Arachidonic Acid as a Key Regulator of Hepatic Lipid Metabolism During Hibernation.” Communications Biology. https://doi.org/10.1038/s42003-026-10625-x.

Woo, Tae-Won, Yoo-Jin Choi, Ji-Yeon Kim, Jin-Seok Lee, and Chang-Gue Son. 2026. “Neuroendocrine Signature of ME/CFS: Meta-Analytic Evidence for Bioactive Cortisol Deficit and Exaggerated Feedback Sensitivity.” Molecular Psychiatry. https://doi.org/10.1038/s41380-026-03608-1.

Wu, Cheng-Wei, and Kenneth B Storey. 2021. “mTOR Signaling in Metabolic Stress Adaptation.” Biomolecules 11 (5): 681. https://doi.org/10.3390/biom11050681.

Xiong, Ruoyun, Elizabeth Aiken, Ryan Caldwell, Suzanne D. Vernon, Lina Kozhaya, Courtney Gunter, Lucinda Bateman, Derya Unutmaz, and Julia Oh. 2025. “AI-Driven Multi-Omics Modeling of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Nature Medicine 31 (9): 2991–3001. https://doi.org/10.1038/s41591-025-03788-3.

Zaki, Nevin F W, Mohamed Yousif, Ahmed S BaHammam, David Warren Spence, Vijay K Bharti, Perumal Subramanian, and Seithikurippu R Pandi-Perumal. 2019. “Chronotherapeutics: Recognizing the Importance of Timing Factors in the Treatment of Disease and Sleep Disorders.” Clinical Neuropharmacology 42 (3): 80–87. https://doi.org/10.1097/WNF.0000000000000341.